Synthetic Antigen-Presenting Cells for Adoptive T Cell Therapy

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Adoptive T cell therapies show promise for treating various cancers.
• Manufacturing functional T cells for therapy is challenging due to unreliable conventional antigen-presenting cells (APCs).
• Engineered nanomaterials offer a controllable and robust alternative for T cell activation.

Purpose of the Study:

• To design and evaluate synthetic APCs for T cell activation and expansion.
• To assess the efficacy of T cells activated by synthetic APCs in preclinical cancer models.

Main Methods:

• Liposomes were functionalized with peptide-major histocompatibility complexes (pMHC) to create synthetic APCs.
• Antigen-specific T cell activation was compared between synthetic APCs and conventional methods.
• In vitro and in vivo studies were conducted using tumor models.

Main Results:

• Synthetic APCs selectively activated antigen-specific T cells, achieving comparable levels to conventional methods without costimulation.
• T cells activated by synthetic APCs exhibited effector functions, including cytokine production and tumor cell killing.
• Adoptive transfer of these T cells controlled tumor growth and improved survival in mice.

Conclusions:

• Synthetic APCs provide a robust and controllable platform for T cell activation, overcoming limitations of conventional APCs.
• This approach has the potential to enhance the manufacturing and accessibility of adoptive T cell therapies.
• Synthetic APCs represent a promising strategy for improving cancer immunotherapy.